Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00

Gilead Sciences (NASDAQ:GILD) had its target price upped by research analysts at Wolfe Research from $155.00 to $170.00 in a report issued on Thursday,MarketScreener reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Wolfe Research’s price target indicates a potential upside of 10.92% from the company’s previous close.

Several other research analysts have also recently weighed in on GILD. Truist Financial lifted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday. Leerink Partners lifted their target price on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. Citigroup boosted their price target on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $150.64.

Gilead Sciences Stock Down 1.6%

GILD stock opened at $153.27 on Thursday. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The business’s 50-day moving average is $129.01 and its two-hundred day moving average is $121.77. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The company has a market cap of $190.16 billion, a price-to-earnings ratio of 22.72, a P/E/G ratio of 0.78 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 51.04% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the company posted $1.90 EPS. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Company insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds have recently modified their holdings of the company. DJE Kapital AG grew its holdings in shares of Gilead Sciences by 71.7% in the fourth quarter. DJE Kapital AG now owns 241,923 shares of the biopharmaceutical company’s stock valued at $29,871,000 after purchasing an additional 101,042 shares in the last quarter. Compass Capital Corp MA ADV bought a new position in Gilead Sciences during the fourth quarter valued at $170,000. ASO GROUP Ltd purchased a new position in shares of Gilead Sciences in the 4th quarter worth $1,333,000. Principal Securities Inc. increased its holdings in shares of Gilead Sciences by 22.7% in the 4th quarter. Principal Securities Inc. now owns 24,949 shares of the biopharmaceutical company’s stock worth $3,062,000 after buying an additional 4,615 shares during the last quarter. Finally, Great Lakes Advisors LLC increased its holdings in shares of Gilead Sciences by 0.9% in the 4th quarter. Great Lakes Advisors LLC now owns 1,022,210 shares of the biopharmaceutical company’s stock worth $125,467,000 after buying an additional 9,394 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom lines — Gilead reported Q4 EPS of $1.86 and revenue of ~$7.9B, ahead of consensus, driven by strong HIV and liver-disease drug sales. This is the primary catalyst for the rally as investors reward visible current cash flow. Reuters: Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades and higher price targets — Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others raised PTs and/or ratings after the print, providing buy-side momentum and supporting the stock’s upside. MarketScreener: Morgan Stanley raises PT
• Positive Sentiment: Dividend hike — Board approved a 3.8% quarterly dividend increase to $0.82/share, raising yield and reinforcing the income case for investors. Dividends often support valuation in large-cap biotech. BusinessWire: Dividend announcement
• Neutral Sentiment: Investment case notes — Commentary highlighting Yescarta label expansion and margin/earnings leverage adds longer-term upside potential but is incremental versus the near-term beat/guidance story. Yahoo Finance: Yescarta and dividend story
• Neutral Sentiment: Earnings materials & transcripts available — For detail on pipeline comments and management tone, see the earnings call transcript and slide deck (useful for modelling but not an immediate stock mover). Seeking Alpha: Q4 earnings call transcript
• Negative Sentiment: FY‑2026 guidance light — Gilead set FY‑26 EPS of $8.45–$8.85 and revenue guidance slightly below consensus (~$29.6–30.0B vs. ~30.1B consensus), which prompted an initial sell-off after hours and is a near-term risk to valuation. MSN: Outlook short of Wall Street view
• Negative Sentiment: Mixed analyst signals — Some firms raised price targets but a few maintained cautious ratings or PTs that imply downside versus current levels (e.g., RBC’s PT remains below the stock), creating a split analyst narrative that could cap upside until guidance clarity improves. Benzinga: analyst actions

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.